First Wave Biopharma Said On September 13, Entered Into A License Agreement With Sanofi; Sanofi To Be Eligible To Get Up To $46M In Potential Development And Regulatory Milestone Payments, Up To $235M In Potential Commercial Milestone Payments
Portfolio Pulse from Charles Gross
First Wave Biopharma has entered into a license agreement with Sanofi. Sanofi could potentially receive up to $46M in development and regulatory milestone payments, and up to $235M in potential commercial milestone payments.
September 14, 2023 | 10:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
First Wave Biopharma has entered into a potentially lucrative license agreement with Sanofi.
The license agreement with Sanofi could potentially bring significant revenue to First Wave Biopharma, which could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Sanofi has entered into a license agreement with First Wave Biopharma, which could potentially bring in up to $281M in milestone payments.
The license agreement with First Wave Biopharma could potentially bring significant revenue to Sanofi, which could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100